Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TK1 | P04183 | 3/20 | 0.73 |
| ▸ | LMNA | P02545 | 2/20 | 0.73 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.73 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.69 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.69 |
| ▸ | TSHR | P16473 | 1/20 | 0.69 |
| ▸ | BLM | P54132 | 1/20 | 0.69 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.69 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.69 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.69 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.69 |
| ▸ | TK2 | O00142 | 1/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Broxuridine SCHEMBL37420 | 1.00 | TK1 (0.73) | TK1LMNASMN1; SMN2CYP1A2CYP3A4 | |
| Broxuridine SCHEMBL10316347 | 1.00 | TK1 (0.73) | TK1LMNASMN1; SMN2CYP1A2CYP3A4 | |
| Broxuridine SCHEMBL65484 | 1.00 | TK1 (0.73) | TK1LMNASMN1; SMN2CYP1A2CYP3A4 | |
| Broxuridine SCHEMBL14457631 | 1.00 | TK1 (0.73) | TK1LMNASMN1; SMN2CYP1A2CYP3A4 | |
| Broxuridine SCHEMBL27756 | 1.00 | TK1 (0.73) | TK1LMNASMN1; SMN2CYP1A2CYP3A4 | |
| Broxuridine SCHEMBL9153195 | 1.00 | TK1 (0.73) | TK1LMNASMN1; SMN2CYP1A2CYP3A4 | |
| Broxuridine SCHEMBL27755 | 1.00 | TK1 (0.73) | TK1LMNASMN1; SMN2CYP1A2CYP3A4 | |
| Broxuridine SCHEMBL20769775 | 1.00 | TK1 (0.73) | TK1LMNASMN1; SMN2CYP1A2CYP3A4 | |
| Broxuridine SCHEMBL21423028 | 1.00 | TK1 (0.73) | TK1LMNASMN1; SMN2CYP1A2CYP3A4 | |
| Broxuridine SCHEMBL5981680 | 1.00 | TK1 (0.73) | TK1LMNASMN1; SMN2CYP1A2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190194746-A1 | NUCLEIC ACID OLIGOMER FOR RNA HYBRID FORMATION | TOKYO UNIVERSITY OF SCIENCE FOUNDATION (JP) | 2019-06-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190194746-A1 | NUCLEIC ACID OLIGOMER FOR RNA HYBRID FORMATION | NSUN3, NSUN2, FBL | TK1 406/4885LMNA 968/4885SMN1; SMN2 1270/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.